Antipodes Partners LTD Alnylam Pharmaceuticals, Inc. Transaction History

Antipodes Partners LTD

$3 Billion
Q2 2025

A detailed history of Antipodes Partners LTD transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 122,804 shares of ALNY stock, worth $56 Million. This represents 1.33% of its overall portfolio holdings.

Number of Shares

122,804

Previous 159,554 23.03%

Holding current value

$56 Million

Previous $43.1 Million 7.05%

% of portfolio

1.33%

Previous 1.36%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 04, 2025	SELL	$224.32 - $326.09 $8.24 Million - $12 Million	-36,750 Reduced 23.03%	122,804 $40 Million
Q1 2025 May 06, 2025	BUY	$233.07 - $290.7 $6.01 Million - $7.5 Million	25,795 Added 19.28%	159,554 $43.1 Million
Q4 2024 Feb 10, 2025	SELL	$232.27 - $300.43 $1.3 Million - $1.69 Million	-5,616 Reduced 4.03%	133,759 $31.5 Million
Q3 2024 Nov 13, 2024	SELL	$233.81 - $287.01 $23.2 Million - $28.5 Million	-99,374 Reduced 41.62%	139,375 $38.3 Million
Q2 2024 Aug 05, 2024	BUY	$143.31 - $247.0 $4.75 Million - $8.19 Million	33,170 Added 16.13%	238,749 $58 Million
Q1 2024 May 06, 2024	BUY	$146.51 - $198.2 $2.41 Million - $3.26 Million	16,438 Added 8.69%	205,579 $30.7 Million
Q4 2023 Jan 24, 2024	BUY	$151.41 - $196.57 $11.7 Million - $15.2 Million	77,307 Added 69.13%	189,141 $36.2 Million
Q3 2023 Nov 09, 2023	BUY	$170.77 - $211.65 $19.1 Million - $23.7 Million	111,778 Added 199603.56%	111,834 $19.5 Million
Q2 2023 Jul 25, 2023	SELL	$185.01 - $212.05 $15,540 - $17,812	-84 Reduced 60.0%	56 $10,000
Q1 2023 May 11, 2023	BUY	$182.66 - $235.53 $4,018 - $5,181	22 Added 18.64%	140 $28,000
Q4 2022 Feb 08, 2023	BUY	$185.53 - $241.31 $21,892 - $28,474	118 New	118 $28,000

Others Institutions Holding ALNY

# of Institutions

744

Shares Held

115M

Call Options Held

584K

Put Options Held

672K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $56.1B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Antipodes Partners LTD, based on Form 13F filings with the SEC.

News

Stay updated on Antipodes Partners LTD with notifications on news.

Account

Antipodes Partners LTD Alnylam Pharmaceuticals, Inc. Transaction History